Business Context and Reporting Period
This Form 8-K Current Report was filed by Gossamer Bio, Inc. on June 17, 2026. The filing discloses the final tender results of an exchange offer for the Company's 5.00% Convertible Senior Notes due 2027. The report also references a special meeting of stockholders scheduled for July 14, 2026, to approve related stockholder proposals.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data disclosed relates to the capital structure reorganization:
- Existing Debt: 5.00% Convertible Senior Notes due 2027.
- New Debt Instrument: Up to $72.0 million in aggregate principal amount of new 7.50% Convertible Senior Secured First Lien Notes due 2030.
- Equity Consideration: Up to 317,647,058 shares of common stock or prefunded warrants (to prevent beneficial ownership exceeding 9.99% for qualified institutional buyers).
- Additional Consideration: Warrants to purchase shares of common stock for eligible holders who tendered prior to the extended early tender date.
Material Changes
The material change reported is the execution of an exchange offer to replace existing convertible notes with a combination of new secured notes, common stock, and warrants. This transaction alters the Company's debt profile by introducing a new 7.50% secured instrument due in 2030 and potentially increasing the number of outstanding shares or warrant obligations.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The Company anticipates benefits from the exchange offer, though it explicitly states that actual results may differ. The transaction requires stockholder approval at the special meeting on July 14, 2026.
Risks and Contingencies:
- The Company may not complete the Exchange Offer on the anticipated timeline or at all.
- Anticipated benefits may not be realized.
- Forward-looking statements are subject to risks described in the Company's Form 10-K and other SEC filings.
Unusual Items: The filing includes a caution that the information contained herein is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated.
Investor Verification Checklist
- Verify the final percentage of Existing Convertible Notes tendered in the exchange offer (specific numbers are not in this text; see Exhibit 99.1).
- Review the definitive proxy statement on Schedule 14A filed on June 9, 2026, for details on the stockholder proposals required for the July 14, 2026, special meeting.
- Confirm the exact number of new shares or prefunded warrants to be issued to avoid dilution exceeding the 9.99% threshold for eligible holders.
- Assess the impact of the new 7.50% secured debt on the Company's liquidity and future interest obligations.